✦ LIBER ✦

Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine

✍ Scribed by David P. Steensma; Julie C. Porcher; Mark R. Litzow; William J. Hogan; Sujata Arora; Emily S. Van Laar

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 98 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.11.030

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical experience with decitabine in N

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

✍ Karen W. L. Yee; Elias Jabbour; Hagop M. Kantarjian; Francis J. Giles 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 127 KB

Outcome of patients with myelodysplastic

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

✍ Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

Quantification of outpatient management

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

✍ J. A. Pitako; P. S. Haas; J. Van den Bosch; H. Müller-Berndorff; A. Kündgen; U. 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 114 KB

A review of 76 patients with myelodyspla

A review of 76 patients with myelodysplastic syndromes treated with danazol

✍ Agustin Avilés; Christian Chabannon; Lysiane Molina; Brigitte Pggouric-Bandelier 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

A review of 76 patients with myelodyspla

A review of 76 patients with myelodysplastic syndromes treated with danazol

✍ Christian Chabannon; Lysiane Molina; Brigitte Pégourié-Bandelier; Mireille Bost; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 776 KB

Survival advantage with decitabine versu

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome : Comparison with historical experience

✍ Hagop M. Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND Decitabine, a hypomethylating agent, is active and has been approved for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Intensive chemotherapy is an accepted form of therapy for patients with higher risk MDS. The comparative efficacy